Læknablaðið - 15.02.2009, Blaðsíða 22

FRÆÐIGREINAR
RANNSÓKNIR
17. Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A.
Seroprevalence of varicella-zoster virus in the German
population. Vaccine 2001; 20:121-4.
18. Boelle PY, Hanslik T. Varicella in non-immune persons:
incidence, hospitalization and mortality rates. Epidemiol
Infect 2002; 129: 599-606.
19. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of
varicella zoster virus infection in Canada and the United
Kingdom. Epidemiol Infect 2001; 127: 305-14.
20. Chant KG, Sullivan EA, Burgess MA, et al. Varicella-zoster
virus infection in Australia.[erratum appears in Aust N Z ]
Public Health 1998; 22: 630]. Aust N Z J Public Health 1998;
22: 413-8.
21. Rawson H, Crampin A, Noah N. Deaths from chickenpox
in England and Wales 1995-7: analysis of routine mortality
data.[see comment]. BMJ 2001; 323:1091-3.
22. Galil K, Brown C, Lin F, Seward J. Hospitalizations for
varicella in the United States, 1988 to 1999. Pediatr Infect Dis
J 2002; 21: 931-5.
23. Ratner AJ. Varicella-related hospitalizations in the vaccine
era. Pediatr Infect Dis J 2002; 21: 927-31.
24. Starko KM, Ray CG, Dominguez LB, Stromberg WL, Woodall
DF. Reye's syndrome and salicylate use. Pediatr 1980; 66:859-
64.
25. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up
of healthy children who received one or two injections of
varicella vaccine. Pediatr Infect Dis J 2004; 23:132-7.
26. Shehab Z, Brunell PA. Enzyme-linked immunosorbent assay
for susceptibility to varicella. J Infect Dis 1983; 148: 472-6.
27. www.hagstofan.is. Mannfjöldi, yfirlit. /ágúst, 2008.
28. Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology
of varicella and its complications. J Infect Dis 1995; 172: 706-
12.
29. Jackson MA, Burry VF, Olson LC. Complications of varicella
requiring hospitalization in previously healthy children.
Pediatr Infect Dis J 1992; 11: 441-5.
30. Ziebold C, von Kries R, Lang R, Weigl J, Schmitt HJ. Severe
complications of varicella in previously healthy children in
Germany: a 1-year survey.[erratum appears in Pediatr 2004;
113:1470]. Pediatr 2001; 108: E79.
31. Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Varicella-
associated invasive group A streptococcal disease in Alberta,
Canada—2000-2002. Clin Infect Dis 2005; 40:1055-7.
32. Balfour HH, Jr. Acyclovir for childhood chickenpox. No
reason not to treat. BMJ 1995; 310:109-10.
33. Miron D, Lavi I, Kitov R, Hendler A. Vaccine effectiveness
and severity of varicella among previously vaccinated
children during outbreaks in day-care centers with low
vaccination coverage. Pediatr Infect Dis J 2005; 24: 233-6.
34. Sheffer R, Segal D, Rahamani S, et al. Effectiveness of the
Oka/GSK attenuated varicella vaccine for the prevention of
chickenpox in clinical practice in Israel. Pediatr Infect Dis J
2005; 24: 434-7.
35. Shinefield H, Black S, Digilio L, et al. Evaluation of a
quadrivalent measles, mumps, rubella and varicella vaccine
in healthy children. Pediatr Infect Dis J 2005; 24: 665-9.
36. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella
virus vaccine. Efficacy trial in healthy children. N Engl J Med
1984; 310:1409-15.
37. Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and
safety of two doses of tetravalent measles-mumps-rubella-
varicella vaccine in healthy children. Pediatr Infect Dis J 2006;
25:12-8.
38. Coudeville L, Paree F, Lebrun T, Sailly J. The value of
varicella vaccination in healthy children: cost-benefit analysis
of the situation in France. Vaccine 1999; 17:142-51.
39. Law B, Fitzsimon C, Ford-Jones L, McCormick J, Riviere M.
Cost of chickenpox in Canada: part II. Cost of complicated
cases and total economic impact. The Immunization
Monitoring Program-Active (IMPACT). Pediatr 1999; 104:
7-14.
>-
CC
<
2
2
D
V)
I
</>
_l
o
z
LU
epidemiology and complications
Varicella in lcelandic children -
Introduction: Varicella is a common disease with possible
consequences. The disease is usually contracted in
childhood and persistent antibodies are produced.
Varicella vaccine is not widely used in lceland. The aim
of the study was to investigate the epidemiology of
varicella in lcelandic children and it's complications. The
results may prove important when deciding on varicella
immunization in lceland.
Material and methods: The study was retrospective cross
sectional. Varicella antibodies were measured from children
<18 years of age. Hospital records of children with varicella
were evaluated.
Results: Serum samples numbered 280. Varicella
antibodies were present in 65% of children <1 year of age
but in 10% of 1-2 year old children. Almost all children had
antibodies before the age of ten and 97.5% of children >10
years had antibodies.
Hospital admittions were 58, annual admittions were
or 3.6/100.000 children <18 years. Bacterial infections,
most frequently skin infections, were the most common
complication, followed by cerebellar ataxia, dehydration
and nutritional deficiency.
Conclusion: Most children in lceland contract varicella
before the age of ten. Substantial complications were
recorded. It is important to recognize varicella, it’s
complications, treatment options and explore whether
varicella vaccination should be instigated in lceland.
Thorarinsdottir H, Löve A, Laxdal Th, Gudnason Th, Haraldsson A. Varicella in lcelandic children - epidemiology
and complications. Icel Med J 2009; 95:113-118.
Key words: varícella, epidemiology, complications, children, infants, immunization.
Correspondence: Asgeir Haraldsson, asgeir@landspitali.is
Barst: 19. september 2008, - samþykkt til birtingar: 16. desember 2008.
1 8 LÆKNAblaðið 2009/95